Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

UBX1325 met safety and efficacy endpoints at 24 weeks in the phase 2 BEHOLD study in patients with diabetic macular edema, according to a press release from Unity Biotechnology.

Laser photocoagulation therapy involves using a laser to create thermal burns on the retina, which seal leaking blood vessels and reduce edema.

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept.

An extension of the PHOTON trial shows that aflibercept 8 mg maintains long-term visual and anatomical improvements in ...

In conclusion, the treatment options for macular edema are constantly evolving, and the emergence of bispecific antibodies, like faricimab, is a game-changer in treating this debilitating condition.

Treatment for Macular Edema At any stage of diabetic retinopathy, fluid can leak from the damaged blood vessels and build up in the center portion of the retina, called the macula, a condition ...

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses the 'bright future' for DME treatment with new drugs coming down the pipeline.

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two treatments per year.

SriniVas Sadda, MD, recalls an encounter with a patient with diabetic macular edema and wonders how the patient would have fared differently today with new technologies.